Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update) Draft guidance consultation NICE guideline 24 February 2025 ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

New and innovative mechanisms of action are constantly being discovered and developed into medicines that tackle a broad ...

Consultation launches on the biggest shake-up of NICE's HealthTech programme to date. More innovative healthcare technologies could soon be adopted by the NHS under reforms proposed today by NICE.

The treatment is recommended for people aged 12 to 65 who have moderate to severe and persistent allergic rhinitis and have been diagnosed through clinical history and a positive test of their house ...

Pembrolizumab (Keytruda, Merck Sharp & Dohme) is indicated for 'the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the elacestrant being ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...